FDA Accepts NDA for Glaukos’ Corneal Cross-Linking Drug Treatment
Glaukos’ Epioxa eyes FDA approval as the first non-invasive cross-linking therapy for keratoconus. Glaukos Corporation (California, USA) announced yesterday that…
AAO-ESCRS Joint Symposium at ESCRS 2024 Tackles Innovations and Controversies in CXL
New options for solving corneal medicine’s toughest challenges are popping up by the day—and a symposium at the 42nd Congress…
latest posts
